Immunovant

Develops drugs for diseases where the immune system attacks the body.

Company Health

/100

Weak

A quick check of the business from its yearly reports (2026). It doesn’t say whether the stock is a good buy.

Does it make money?

0 of 25 · Poor

It doesn’t sell much yet, and it lost money last year.

Can it handle what it owes?

25 of 25 · Good

It holds more cash than everything it owes.

Does it bring in spare cash?

0 of 25 · Poor

It spent more cash than it brought in last year.

Who owns it

1 of 23 own it · Nobody changed their stake

bought lately

owns it

doesn’t own it

Didn’t report owning it: Whale Rock, Appaloosa, Melqart, Coatue, D1 Capital, Light Street, Lone Pine, Third Point, TCI, Pershing Square, Duquesne, Himalaya Capital, Giverny Capital, Fundsmith, Semper Augustus, Akre

Their letters don’t mention it: Arquitos, Laughing Water, Alluvial, Bireme, Kingdom Capital, Saga Partners

From each fund’s latest 13F report (Jun 30, 2026). Funds that don’t file one: from their own letters.

The numbers

From Immunovant’s yearly reports. Tap a year to see its figures.

Sales and profit

It lost money every year.

FY2026

Loss

$506 million

Spare cash each year

It spent more cash than it brought in every year: $407 million more in the year to Mar 2026.

FY2026

Cash shortfall

$407 million

Spare cash is the cash its business brought in, minus what it spent on buildings and equipment.

What it owns and what it owes

At the end of Mar 2026 it owned $957 million, including $902 million in cash, and owed $104 million.

Key facts

From its yearly report for the year to Mar 2026.

Loss

$506 million

Cash shortfall

$407 million

Cash in the bank

$902 million

Everything it owes

$104 million

Year ends

March

Money shown in

U.S. dollars

Latest yearly report

10-K, filed May 20, 2026

Figures from Immunovant’s yearly reports to the SEC (EDGAR), collected Oct 12, 2026.

Not investment advice. Holdings come from public SEC reports and the funds’ own letters, and can be up to 4½ months old. How this works